Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Oliver P. Günther, Jennifer L. Gardy, Phillip Stafford, Øystein Fluge, Olav Mella, Patrick Tang, Ruth R. Miller, Shoshana M. Parker, Stephen Johnston, David M. Patrick

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A random-sequence peptide microarray can interrogate serum antibodies in a broad, unbiased fashion to generate disease-specific immunosignatures. This approach has been applied to cancer detection, diagnosis of infections, and interrogation of vaccine response. We hypothesized that there is an immunosignature specific to ME/CFS and that this could aid in the diagnosis. We studied two subject groups meeting the Canadian Consensus Definition of ME/CFS. ME/CFS (n = 25) and matched control (n = 25) sera were obtained from a Canadian study. ME/CFS (n = 25) sera were obtained from phase 1/2 Norwegian trials (NCT01156909). Sera from six healthy controls from the USA were included in the analysis. Canadian cases and controls were tested for a disease immunosignature. By combining results from unsupervised and supervised analyses, a candidate immunosignature with 654 peptides was able to differentiate ME/CFS from controls. The immunosignature was tested and further refined using the Norwegian and USA samples. This resulted in a 256-peptide immunosignature with the ability to separate ME/CFS cases from controls in the international data sets. We were able to identify a 256-peptide signature that separates ME/CFS samples from healthy controls, suggesting that the hit-and-run hypothesis of immune dysfunction merits further investigation. By extending testing of both our signature and one previously reported in the literature to larger cohorts, and further interrogating the specific peptides we and others have identified, we may deepen our understanding of the origins of ME/CFS and work towards a clinically meaningful diagnostic biomarker.

Original languageEnglish (US)
JournalMolecular Neurobiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Chronic Fatigue Syndrome
Peptides
Serum
Aptitude
Group Processes

Keywords

  • Diagnosis
  • Immunosignatures
  • Myalgic encephalomyelitis/chronic fatigue syndrome
  • Peptides

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Günther, O. P., Gardy, J. L., Stafford, P., Fluge, Ø., Mella, O., Tang, P., ... Patrick, D. M. (Accepted/In press). Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1354-8

Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). / Günther, Oliver P.; Gardy, Jennifer L.; Stafford, Phillip; Fluge, Øystein; Mella, Olav; Tang, Patrick; Miller, Ruth R.; Parker, Shoshana M.; Johnston, Stephen; Patrick, David M.

In: Molecular Neurobiology, 01.01.2018.

Research output: Contribution to journalArticle

Günther, OP, Gardy, JL, Stafford, P, Fluge, Ø, Mella, O, Tang, P, Miller, RR, Parker, SM, Johnston, S & Patrick, DM 2018, 'Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)', Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1354-8
Günther, Oliver P. ; Gardy, Jennifer L. ; Stafford, Phillip ; Fluge, Øystein ; Mella, Olav ; Tang, Patrick ; Miller, Ruth R. ; Parker, Shoshana M. ; Johnston, Stephen ; Patrick, David M. / Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). In: Molecular Neurobiology. 2018.
@article{eeb3461c946143aaa33c489530b72484,
title = "Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)",
abstract = "A random-sequence peptide microarray can interrogate serum antibodies in a broad, unbiased fashion to generate disease-specific immunosignatures. This approach has been applied to cancer detection, diagnosis of infections, and interrogation of vaccine response. We hypothesized that there is an immunosignature specific to ME/CFS and that this could aid in the diagnosis. We studied two subject groups meeting the Canadian Consensus Definition of ME/CFS. ME/CFS (n = 25) and matched control (n = 25) sera were obtained from a Canadian study. ME/CFS (n = 25) sera were obtained from phase 1/2 Norwegian trials (NCT01156909). Sera from six healthy controls from the USA were included in the analysis. Canadian cases and controls were tested for a disease immunosignature. By combining results from unsupervised and supervised analyses, a candidate immunosignature with 654 peptides was able to differentiate ME/CFS from controls. The immunosignature was tested and further refined using the Norwegian and USA samples. This resulted in a 256-peptide immunosignature with the ability to separate ME/CFS cases from controls in the international data sets. We were able to identify a 256-peptide signature that separates ME/CFS samples from healthy controls, suggesting that the hit-and-run hypothesis of immune dysfunction merits further investigation. By extending testing of both our signature and one previously reported in the literature to larger cohorts, and further interrogating the specific peptides we and others have identified, we may deepen our understanding of the origins of ME/CFS and work towards a clinically meaningful diagnostic biomarker.",
keywords = "Diagnosis, Immunosignatures, Myalgic encephalomyelitis/chronic fatigue syndrome, Peptides",
author = "G{\"u}nther, {Oliver P.} and Gardy, {Jennifer L.} and Phillip Stafford and {\O}ystein Fluge and Olav Mella and Patrick Tang and Miller, {Ruth R.} and Parker, {Shoshana M.} and Stephen Johnston and Patrick, {David M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12035-018-1354-8",
language = "English (US)",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press",

}

TY - JOUR

T1 - Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

AU - Günther, Oliver P.

AU - Gardy, Jennifer L.

AU - Stafford, Phillip

AU - Fluge, Øystein

AU - Mella, Olav

AU - Tang, Patrick

AU - Miller, Ruth R.

AU - Parker, Shoshana M.

AU - Johnston, Stephen

AU - Patrick, David M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A random-sequence peptide microarray can interrogate serum antibodies in a broad, unbiased fashion to generate disease-specific immunosignatures. This approach has been applied to cancer detection, diagnosis of infections, and interrogation of vaccine response. We hypothesized that there is an immunosignature specific to ME/CFS and that this could aid in the diagnosis. We studied two subject groups meeting the Canadian Consensus Definition of ME/CFS. ME/CFS (n = 25) and matched control (n = 25) sera were obtained from a Canadian study. ME/CFS (n = 25) sera were obtained from phase 1/2 Norwegian trials (NCT01156909). Sera from six healthy controls from the USA were included in the analysis. Canadian cases and controls were tested for a disease immunosignature. By combining results from unsupervised and supervised analyses, a candidate immunosignature with 654 peptides was able to differentiate ME/CFS from controls. The immunosignature was tested and further refined using the Norwegian and USA samples. This resulted in a 256-peptide immunosignature with the ability to separate ME/CFS cases from controls in the international data sets. We were able to identify a 256-peptide signature that separates ME/CFS samples from healthy controls, suggesting that the hit-and-run hypothesis of immune dysfunction merits further investigation. By extending testing of both our signature and one previously reported in the literature to larger cohorts, and further interrogating the specific peptides we and others have identified, we may deepen our understanding of the origins of ME/CFS and work towards a clinically meaningful diagnostic biomarker.

AB - A random-sequence peptide microarray can interrogate serum antibodies in a broad, unbiased fashion to generate disease-specific immunosignatures. This approach has been applied to cancer detection, diagnosis of infections, and interrogation of vaccine response. We hypothesized that there is an immunosignature specific to ME/CFS and that this could aid in the diagnosis. We studied two subject groups meeting the Canadian Consensus Definition of ME/CFS. ME/CFS (n = 25) and matched control (n = 25) sera were obtained from a Canadian study. ME/CFS (n = 25) sera were obtained from phase 1/2 Norwegian trials (NCT01156909). Sera from six healthy controls from the USA were included in the analysis. Canadian cases and controls were tested for a disease immunosignature. By combining results from unsupervised and supervised analyses, a candidate immunosignature with 654 peptides was able to differentiate ME/CFS from controls. The immunosignature was tested and further refined using the Norwegian and USA samples. This resulted in a 256-peptide immunosignature with the ability to separate ME/CFS cases from controls in the international data sets. We were able to identify a 256-peptide signature that separates ME/CFS samples from healthy controls, suggesting that the hit-and-run hypothesis of immune dysfunction merits further investigation. By extending testing of both our signature and one previously reported in the literature to larger cohorts, and further interrogating the specific peptides we and others have identified, we may deepen our understanding of the origins of ME/CFS and work towards a clinically meaningful diagnostic biomarker.

KW - Diagnosis

KW - Immunosignatures

KW - Myalgic encephalomyelitis/chronic fatigue syndrome

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=85055016664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055016664&partnerID=8YFLogxK

U2 - 10.1007/s12035-018-1354-8

DO - 10.1007/s12035-018-1354-8

M3 - Article

C2 - 30298340

AN - SCOPUS:85055016664

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

ER -